We are much obliged to Gottschalk et al. [1] for the clarification of the morphological classification of Brugada syndrome (BrS). As suggested initially, we were describing Brugada phenocopy (BrP) with myocardial ischemia [2] . This was ruled out after a positive Ajmaline test for BrS.
Dear Editor,
We are much obliged to Gottschalk et al. [1] for the clarification of the morphological classification of Brugada syndrome (BrS). As suggested initially, we were describing Brugada phenocopy (BrP) with myocardial ischemia [2] . This was ruled out after a positive Ajmaline test for BrS.
As pointed out by Gottschalk et al., we initially felt that the co-existence of coronary artery disease and BrS places the patient at high risk for adverse cardiac events. However, after the revascularisation of the right coronary artery (RCA), the patient had a treadmill exercise test (ETT), and a one-week monitor evaluation, both of these tests did not show any significant dysrhythmias or ischemia. During his clinic visit, details of history were taken, and no previous family history of sudden death was identified. Also, it was noted that there was no clinical history of syncope. As per the latest HRS/EHRA/APHRS consensus statement, we offered him the following therapeutic interventions: lifestyle changes advice involving avoidance of drugs that may induce or aggravate ST segment elevation in right precordial leads (Brugadadrugs.org), avoidance of excessive alcohol intake, and immediate treatment of fever with antipyretic drugs [3] . The option of implantable cardiac defibrillator (ICD) therapy was raised and discussed, however, as he remained a completely asymptomatic BrS patient with no family history of sudden cardiac death, a multidisciplinary team including the patient decided against it. He remains under our active vigilant follow-up in the inherited cardiac condition clinic where detailed history is revisited, and lifestyles modifications are reemphasised.
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